FDA
-
-
-
-
-
-
-
Nuvation Bio partners with Eisai for taletrectinib in Europe
-
-
-
-
-
-
-
Nuvation Bio begins phase 3 trial of safusidenib for brain cancer
-
-
-
-
-
-
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Nuvation Bio Inc (NUVB)
-
-
-
-
-
-
-
Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025
-
-
-
-
-
-
-
Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners
-
-
-
-
-
-
-
Nuvation Bio (NUVB) Announces FDA Acceptance for Priority Review of New Drug Application for Taletrectinib
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

